title: Key points of basic theories and clinical practice in rAd-p53 ( Gendicine ™) gene therapy for solid malignant tumors.
abstract: BACKGROUND
  Wild-type p53 gene is an essential cancer suppressor gene which plays an important role in carcinogenesis and malignant progressions. The p53 gene family participates in almost all the key procedures of cancer biology, such as programmed cell death, angiogenesis, metabolism and epithelial-mesenchymal transition. The mutation or functional defects of the p53 gene family are detected in most of the solid malignant tumors, and the restoration of the p53 gene by adenovirus-mediated gene therapy becomes a promising treatment for cancer patients now.
  
  
  METHODS
  In the present review, the potential therapeutic effects of recombinant adenovirus p53 rAd-p53 ( Gendicine ™) were reviewed to explore the biological mechanism underlying the adenovirus-mediated p53 gene therapy. Then, the key points of the drug administration were discussed, including the routes of administration, dosage calculation and treatment cycles, based on findings of the preclinical and clinical trials in order to establish a standard treatment for the p53 gene therapy.
  
  
  CONCLUSIONS
  As an important part of the combined therapy for the cancer patients, the adenovirus-mediated p53 gene therapy was blossomed to be a promising treatment strategy. A new evaluation criteria and guideline for the gene therapy is urgently needed for the further clinical practice.
authors.affiliation: Sichuan University, West China Hospital of Stomatology, State Key Laboratory of Oral Disease , Chengdu, 610041 , China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Li
authors.forename: Bo
authors.initials: B
authors.lastname: Li
authors.forename: Chun-Jie
authors.initials: CJ
authors.lastname: Li
authors.forename: Long-Jiang
authors.initials: LJ
authors.lastname: Li
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D017209:Apoptosis / Q000235:genetics; D002986:Clinical Trials as Topic / Q000379:methods; D016158:Genes, p53 / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics; D006801:Humans; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000235:genetics
chemical_list: D011994:Recombinant Proteins
keywords: basic theory; clinical practice; gene therapy; recombinant adenovirus p53; solid cancer